‘Practice-changing’ radioligand therapy may ‘redefine’ treatment of neuroendocrine tumors

Adding radioligand therapy to first-line treatment of grade 2 or grade 3 gastroenteropancreatic neuroendocrine tumors conferred a significant reduction in risk for disease progression or death, results of a randomized study showed.
Adults who received the radioligand therapy lutetium Lu 177 dotatate (Lutathera, Novartis) had 30% higher overall response rate than the study’s control group, according to findings at ASCO Gastrointestinal Cancers Symposium.
“These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart